GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » Altman Z-Score
中文

MusclePharm (MusclePharm) Altman Z-Score : -28.76 (As of Apr. 24, 2024)


View and export this data going back to 2008. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

MusclePharm has a Altman Z-Score of -28.76, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for MusclePharm's Altman Z-Score or its related term are showing as below:


MusclePharm Altman Z-Score Historical Data

The historical data trend for MusclePharm's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MusclePharm Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.23 -8.76 -19.12 -16.31 -27.25

MusclePharm Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.20 -20.07 -22.59 -27.25 -28.65

Competitive Comparison

For the Packaged Foods subindustry, MusclePharm's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MusclePharm Altman Z-Score Distribution

For the Consumer Packaged Goods industry and Consumer Defensive sector, MusclePharm's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where MusclePharm's Altman Z-Score falls into.



MusclePharm Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

MusclePharm's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-3.0336+1.4*-17.6872+3.3*-1.3756+0.6*0.0008+1.0*4.1765
=-28.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2022:
Total Assets was $11.98 Mil.
Total Current Assets was $11.84 Mil.
Total Current Liabilities was $48.17 Mil.
Retained Earnings was $-211.84 Mil.
Pre-Tax Income was -6.301 + -6.824 + -3.901 + -2.244 = $-19.27 Mil.
Interest Expense was -0.638 + -0.834 + -0.683 + -0.64 = $-2.80 Mil.
Revenue was 13.101 + 10.042 + 11.971 + 14.908 = $50.02 Mil.
Market Cap (Today) was $0.04 Mil.
Total Liabilities was $50.03 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(11.838 - 48.171)/11.977
=-3.0336

X2=Retained Earnings/Total Assets
=-211.84/11.977
=-17.6872

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-19.27 - -2.795)/11.977
=-1.3756

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.041/50.032
=0.0008

X5=Revenue/Total Assets
=50.022/11.977
=4.1765

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

MusclePharm has a Altman Z-Score of -28.76 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


MusclePharm  (OTCPK:MSLPQ) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


MusclePharm Altman Z-Score Related Terms

Thank you for viewing the detailed overview of MusclePharm's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MusclePharm (MusclePharm) Business Description

Traded in Other Exchanges
N/A
Address
6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118
MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.
Executives
Eric Chin officer: Chief Accounting Officer 1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr director BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi officer: President & CFO 6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller director 4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc. 10 percent owner 1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc 10 percent owner C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney 10 percent owner 4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc 10 percent owner 265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell 10 percent owner 8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond director 10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123